Menopause Market Report 2026

The menopause market size has grown strongly in recent years. It will grow from $18.78 billion in 2025 to $19.95 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to aging female population, increased life expectancy among women, widespread use of hormone replacement therapy, growing awareness of menopausal symptoms, expansion of women’s healthcare services.

The menopause market size is expected to see strong growth in the next few years. It will grow to $26.21 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to rising demand for safer long-term therapies, growth in menopause-focused digital health platforms, increasing focus on preventive women’s health, expansion of online pharmacy access, greater acceptance of alternative and lifestyle-based treatments. Major trends in the forecast period include growing adoption of non-hormonal menopause treatments, rising awareness and proactive menopause management, increasing preference for dietary supplements and natural remedies, expansion of personalized menopause care programs, higher demand for symptom-specific treatment solutions.

The rise in changing lifestyles is expected to drive the growth of the menopause market in the coming years. A changing lifestyle refers to modifications in the way individuals live and make decisions that influence their health and overall well-being. During this natural biological stage, lifestyle modifications can help manage menopausal symptoms and improve overall health. Menopause can encourage changes in lifestyle habits in several ways, such as maintaining a balanced diet, engaging in regular physical activity, ensuring adequate sleep, avoiding smoking and excessive alcohol consumption, and participating in relaxing or stress-reducing activities. For instance, in November 2023, according to a press release by the Global Wellness Institution, a US-based organization, the wellness economy accounted for 5.6% of global economic output in 2022 and is projected to reach $8.5 trillion by 2027, growing at an average annual rate of 8.6%. Therefore, the growing shift toward healthier lifestyles is contributing to the expansion of the menopause market.

Major companies operating in the menopause market are emphasizing the development of innovative therapies, including dual neurokinin 1/neurokinin 3 (NK1/NK3) receptor antagonists, to provide hormone-free options for managing vasomotor symptoms such as hot flashes and night sweats and to enhance the overall quality of life for menopausal women. Dual neurokinin 1/neurokinin 3 receptor antagonists are oral drugs designed to concurrently inhibit both NK1 and NK3 receptors in the hypothalamus, thereby regulating neuropeptide pathways involved in thermoregulation and sweating and reducing the frequency and intensity of hot flashes as well as related sleep disturbances. For example, in October 2025, Bayer AG, a Germany-based pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for Lynkuet (elinzanetant) 60 mg capsules, the world’s first dual-NK1/NK3 receptor antagonist approved for treating moderate to severe menopausal hot flashes. Lynkuet provides once-daily bedtime dosing, delivers substantial reductions in both the frequency and severity of hot flashes as shown in three Phase III trials (OASIS 1/2/3), and features a non-hormonal mechanism of action that expands treatment choices for women who are not suitable candidates for hormone therapy.

In December 2023, Theramex HQ UK Limited, a UK-based global specialty pharmaceutical company dedicated to women’s health, acquired the Femoston and Duphaston hormone replacement therapy portfolio in Europe from Viatris Inc. for an undisclosed consideration. Through this acquisition, Theramex seeks to reinforce its menopause treatment offerings by broadening access to well-established hormone replacement therapies used to manage menopausal symptoms across several European markets. Viatris Inc., a US-based pharmaceutical company that provides menopause therapies, previously held the European rights to Femoston and Duphaston.

Major companies operating in the menopause market are Pfizer Inc., Johnson & Johnson Inc., The Procter & Gamble Company, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A, Abbott Laboratories Ltd., GSK plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Rainbow Light Nutritional Systems LLC, Mithra Pharmaceuticals SA, TherapeuticsMD Inc., Theramex SpA, Pure Encapsulations LLC., Mylan N.V., Serenity Pharmaceuticals LLC.

North America was the largest region in the menopause market in 2025. The regions covered in the menopause market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the menopause market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the menopause market by increasing costs associated with imported pharmaceutical ingredients, dietary supplements, and formulation inputs used in both hormonal and non-hormonal products. The impact is most evident across hormone replacement therapies and premium supplements, particularly in regions dependent on imports such as Asia-Pacific and Latin America. Higher input costs have affected pricing across hospital, retail, and online pharmacy channels. However, tariffs have also encouraged local manufacturing, generic product development, and diversified sourcing strategies, supporting long-term market accessibility.

The menopause market research report is one of a series of new reports that provides menopause market statistics, including menopause industry global market size, regional shares, competitors with a menopause market share, detailed menopause market segments, market trends and opportunities, and any further data you may need to thrive in the menopause industry. This menopause market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Menopause is a natural biological process that signifies the conclusion of a woman’s menstrual cycles and reproductive phase, typically confirmed after 12 consecutive months without menstruation. It is commonly accompanied by a range of physical and hormonal changes that indicate the end of reproductive function, as the ovaries cease releasing eggs and the levels of progesterone and estrogen decline.

The primary treatments for menopause include dietary supplements and over-the-counter (OTC) pharmaceutical products. A dietary supplement is a substance that, unlike conventional food, is intended to support and enhance the diet. These treatments are administered through topical, oral, and injectable routes and are distributed via hospitals, retail pharmacies, and online pharmacies, with use across hospitals, diagnostic centers, specialty clinics, and other end-user settings.

The menopause market includes revenues earned by entities by providing hormone replacement therapies, selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.